Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FORRAD (also known as Oral Ulcer Gargle) is a proprietary mucoadhesive hydrogel formulation developed for the management of radiation-induced oral mucositis (stomatitis). It is primarily indicated for patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy (IMRT). The formulation works by creating a viscous, protective barrier over the oral mucosa, which shields the tissue from further injury and provides a palliative effect to facilitate healing. In clinical studies led by Yun-fei Xia at Sun Yat-sen University Cancer Center, FORRAD has been evaluated in Phase 2 trials to compare its efficacy and safety against a standard quadruple mixture of dexamethasone, gentamicin, vitamin B12, and procaine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FORRAD (Forrad Pharmaceutical).